MIST Stock Risk & Deep Value Analysis
MIST
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on MIST
We analyzed MIST using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MIST through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
MIST Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About MIST (MIST)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$205.26M
MIST Deep Value Analysis
MIST Red Flags & Warning Signs
- âš
Lower-than-expected etripamil sales and prescription growth, indicating slow market adoption
- âš
Need for additional dilutive financing due to high cash burn and insufficient revenue ramp-up
- âš
Unexpected safety signals or post-marketing issues with etripamil
- âš
Introduction of a competitive non-invasive therapy for acute PSVT by a larger pharmaceutical company
Unlock MIST Red Flags & Risk Warnings
Create a free account to see the full analysis
MIST Financial Health Metrics
Market Cap
$205.26M
MIST Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily built on patent protection for etripamil, which offers a period of exclusivity (likely 10-15 years from approval). Physician and patient comfort with at-home self-administration could create strong brand loyalty and resistance to switching, enhancing durability beyond pure patent life.
MIST Competitive Moat Analysis
Sign up to see competitive advantages
MIST Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Late Jan / Early Feb 2026), providing first commercialization insights
- •Initial prescription and net sales data for etripamil, demonstrating early adoption
- •Updates on physician and patient feedback regarding etripamil's convenience and efficacy
Medium-Term (6-18 months)
- •Continued growth in etripamil net sales and market penetration through Q1 and Q2 2026
- •Potential initiation of ex-U.S. regulatory filings or partnership discussions for etripamil
- •Further clinical data or label expansion studies for etripamil in other indications
Long-Term (18+ months)
- •Etripamil establishing itself as the standard of care for acute PSVT treatment globally
- •Expansion of pipeline products or additional indications for etripamil leveraging platform technology
- •Achievement of sustainable profitability and positive cash flow generation
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
MIST Bull Case: What Could Go Right
- ✓
Consistent quarter-over-quarter acceleration in etripamil net sales and prescription volume
- ✓
Updates on ex-U.S. regulatory progress or new strategic commercial partnerships
- ✓
Maintenance or improvement of cash runway projections and efficient capital allocation
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
